Advertisement

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Amit Sanyal, MD: A Clinician’s Perspective

Advertisement

Advertisement

Jan

14

Today In Oncology

Nivolumab Plus AVD Reduces Disease Progression Risk in Advanced Classical Hodgkin Lymphoma

WGS-Based Classifier Better Predicts HRD Across Cancer Types

ACS Report Shows 5-Year Survival Rate for All Cancers Combined Has Reached 70%

Can DNA Testing of Colorectal Polyps Improve Insight Into Genetic Risks

Pirtobrutinib vs Ibrutinib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Advertisement

© 2026 HSP News Service, L.L.C.